These findings suggest that GRP78/BiP induction could represent a therapeutic strategy targeting drug-resistant cells associated with lung, bladder, and breast cancers, whereas GRP78/BiP inhibition might be effective against resistant cells associated with gastric cancer, transformed fibroblasts, and epidermoid carcinoma. This evidence concerns the gene HSPA5 and breast carcinoma.